Pelthos Therapeutics Inc. (PTHS) Stock

About Pelthos Therapeutics Inc.

Pelthos Therapeutics Inc. operates as a biopharmaceutical enterprise dedicated to developing and commercializing innovative medical treatments that address significant, unmet patient needs. Its primary offerings include ZELSUVMI, a medication specifically indicated for the treatment of molluscum contagiosum in individuals aged one year and older. Furthermore, the company leverages NITRICIL, an exclusive technological platform grounded in nitric oxide research. Established in 2002, this Durham, North Carolina-based firm was previously known as Channel Therapeutics Corporation, before rebranding to Pelthos Therapeutics Inc. in July 2025.

Pelthos Therapeutics Inc. is led by CEO Scott Plesha, employs 4 people, headquartered in US, publicly traded since 2025.

Pelthos Therapeutics Inc. (PTHS) stock trades at $17.00 with a market capitalization of $65.08M. The stock is valued at a negative price-to-earnings (P/E) ratio of -0.48, reflecting a net loss over the last twelve months, a negative price-to-book of -47.77, reflecting negative shareholders' equity, price-to-sales of 1.79. Over the past 52 weeks the stock has ranged between $17.00 and $37.50, and currently trades 54.7% below its 52-week high.

On profitability, Pelthos Therapeutics Inc. generates a return on equity (ROE) of -218.94% (not meaningful, as shareholders' equity is negative), return on capital employed of -54.82%, an operating margin of -188.24%, a net profit margin of -165.24%.

Official website: pelthos.com

Pelthos Therapeutics Inc. by the numbers, 2020–2025

Between 2020 and 2025 Pelthos Therapeutics Inc. reported revenue of $0 rising to $17.0M. Compounded, revenue has grown —% a year over five years, —% over three, —% over the last twelve months. Net profit fell to $-43.0M.

Operating margin went from -677.2% in 2020 to -193.1% in 2025, a gain of 484.1 percentage points. The most recent net margin is -165.24%. On a trailing twelve-month basis to Jun '26, revenue is $43.0M and net profit $-71.0M.

Borrowings stand at $35.0M, cash on hand is $25.0M, cash from operations was $-23.0M in the latest year, positive in 0 of the last 6.

Return on equity has averaged 80.8% over five years, and was -110.3% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Pelthos Therapeutics Inc. (PTHS) — frequently asked questions